|
시장보고서
상품코드
1906685
재조합 알부민 시장 규모와 예측(2021-2031년) - 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 원료별, 용도별, 최종사용자별Recombinant Albumin Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Source, Application, and End User |
||||||
당사의 새로운 연구 '2031년까지 재조합 알부민 시장 예측(-2031년) - 세계 분석 - 용도별 및 최종 사용자별 분석'에 따르면, 시장 규모는 2024년 3억 9,250만 달러에서 2031년까지 7억 6,754만 달러로 성장할 것으로 예측되며, 2025년부터 2031년까지 10.1%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 성장은 간 질환 및 관련 질환 증가, 생명공학 제조 기술 및 제품 개발의 발전, 중환자실 및 응급의료 현장에서의 알부민 수요 증가에 기인합니다.
재조합 알부민은 효모(Pichia pastoris, Saccharomyces cerevisiae), 쌀(Oryza sativa), 또는 세균(E. coli)등의 숙주 생물에서 유전자 공학에 의해서 생산되는 합성 비동물 유래 인간 혈청알부민(HSA)입니다.천연 HSA와 아미노산 배열이 100%동일하면서, 혈장 유래 알부민에 관련된 혈액 매개 병원체, 프리온, 바이러스 오염물질을 완전하게 배제하고 있습니다.재조합 알부민은 cGMP 조건하에서 제조되어 우수한 로트간 균일성, 확장성, 규제상 안전성을 제공합니다.본품은 바이오세라퓨티크스나 백신 안정화제/부형제로서 또 생물학적 제제나 세포/유전자 치료용 무혈청 세포배양 배지 중요 성분으로서 넓게 사용되고 있습니다. 또한 저알부민혈증, 간질환, 재생의료 용도 새로운 치료법으로서도 주목받고 있습니다.
북미 재조합 알부민 시장은 미국, 캐나다, 멕시코로 구분됩니다. 보다 안전하고 균일한 혈장 단백질 제품에 대한 임상적 수요가 증가함에 따라 북미 재조합 알부민 시장은 괄목할 만한 성장세를 보이고 있습니다. 미국 식품의약국(FDA)에 따르면 간경화, 화상, 쇼크 등 알부민 요법이 필요한 질환의 유병률이 크게 증가하고 있습니다. 미국 질병예방통제센터(CDC)의 보고에 따르면, 2023년 기준 미국에서는 연간 약 4만 건의 새로운 간경변증 환자가 발생할 것으로 추정됩니다. 재조합 알부민의 채택 확대는 생명공학 기술의 발전으로 안전하고 생산 규모를 확대할 수 있는 윤리적으로 지속 가능한 제품 개발로 뒷받침되고 있습니다. 특히 2022년에는 FDA가 혈장 유래 제품 대비 병원체 전파 위험을 감소시키는 새로운 재조합 알부민 제제를 승인하여 안전성 우려에 대응했습니다. 집중치료 및 종양학용 재조합 알부민 기반 치료제 출시 등 지속적인 연구와 제품 혁신이 시장 확대를 촉진하고 있습니다. 정부의 이니셔티브, 특히 생명공학 연구에 대한 자금 지원과 혈장 유래 제품에 대한 규제 강화는 유전자 재조합 대체품으로의 전환을 촉진하고 있습니다. 코로나19 팬데믹은 신뢰할 수 있는 바이오의약품의 중요성을 부각시켰고, 시장 성장을 더욱 가속화했습니다. 2024년 현재, 규제 당국은 재조합 알부민을 알부민 치료에서 보다 안전한 선택으로 계속 권장하고 있습니다.
미국에서는 더 안전한 생물학적 제제에 대한 수요, 간 질환의 유병률 증가, 규제 요구 사항의 진화가 두드러집니다. 최근 연구에 따르면 미국 성인 인구의 2.6%가 간경변증을 앓고 있는 것으로 나타났습니다. 간경변증 환자는 저알부민혈증이 자주 발생하여 알부민 투여가 필요합니다. 미국 식품의약국(FDA)은 2024년 4월 '세포-유전자치료 및 조직공학 의료제품 제조 시 인간 및 동물 유래 물질의 사용에 대한 고려사항'이라는 제목의 지침 초안을 발표했습니다. 이번 초안에서 FDA는 알부민, 배지 등 인체 유래 및 동물 유래 물질의 첨단치료제 사용에 대한 우려를 강조하고, 제조업체들이 대체 물질의 채택을 정당화할 것을 촉구했습니다. 이러한 규제 동향으로 인해 재조합 인간 혈청 알부민(rHSA)을 비롯한 비혈장 유래 알부민 제품은 보다 안전하고 정의된 대체품으로 유리한 입장에 서게 되었습니다.
혈장 유래 알부민을 대체할 수 있는 치료적 대안이 미래 시장 기회를 제공합니다.
재조합 알부민의 주요 기회는 치료용 혈장 유래 인간 혈청 알부민(HSA)을 대체하여 안전성과 혈장 공급의 제약에 대응하는 것입니다. 중국 우한시 위생건강위원회에 따르면, 2024년 인간 알부민 수요는 1,000톤을 넘어섰고, 수입이 총 공급량의 69% 이상을 차지할 것으로 예상했습니다. 국가약품감독관리국(NMPA)은 혈장 수입 의존도를 낮추기 위해 2025년 7월 우한헬스젠바이오테크놀러지가 개발한 세계 최초의 쌀 유래 재조합 인간 알부민 주사제를 승인했습니다. 인도에서는 실파메디케어가 2024년 8월 국내 기업 최초로 재조합 인간알부민(20%) 임상 1상을 완료하고, 2024년 11월 중앙의약품규제감시기구(CDSCO)로부터 임상 3상 시험 승인을 받았습니다. 이러한 규제적 진전은 재조합 기술에 대한 신뢰가 높아지고 있음을 보여줍니다. 전 세계적으로 간경변증과 저알부민혈증이 증가하고 있는 가운데, 재조합 알부민은 확장성이 있고 병원균을 포함하지 않는 치료 대안으로 기대를 모으고 있습니다.
목차
제1장 도입
제2장 주요 요약
- 애널리스트 시장 전망
- 시장의 매력
제3장 조사 방법
- 2차 조사
- 1차 조사
- 가설 책정
- 거시경제적 요인 분석
- 기준치 산출
- 데이터 삼각측량
- 국가 레벨 데이터
- 전제조건과 제한 사항
제4장 재조합 알부민 시장 구도
- PEST 분석
- 생태계 분석
- 밸류체인 벤더 리스트
제5장 재조합 알부민 시장-주요 시장 역학
- 재조합 알부민 시장-주요 시장 역학
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 향후 동향
- 성장 촉진요인과 억제요인의 영향
제6장 재조합 알부민 시장-세계 시장 분석
- 재조합 알부민 시장 매출(2021년-2031년)
- 재조합 알부민 시장 예측 분석
제7장 재조합 알부민 시장 분석-원료별
- 인간 유래 재조합 알부민
- 우유래 재조합 알부민
- 기타 원료
제8장 재조합 알부민 시장 분석-용도별
- 바이오의약품 및 백신 첨가제
- 세포배양
- 약물전달
- 진단
- 기타 용도
제9장 재조합 알부민 시장 분석-최종사용자별
- 제약 기업 및 바이오테크놀러지 기업
- 연구기관
- 병원 및 진단실험실
- 기타 최종사용자
제10장 재조합 알부민 시장-지역 분석
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
- 아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양 기타 국가
- 중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
- 남미 및 중남미
- 브라질
- 아르헨티나
- 기타 남미·중앙아메리카 기타 지역
제11장 경쟁 구도
- 주요 기업별 히트맵 분석
- 기업 점유율 분석(2024년)
제12장 업계 상황
- 시장 이니셔티브
- 인수합병(M&A)
- 기타 동향
제13장 기업 개요
- CSL Ltd
- Merck KGaA
- HiMedia Laboratories Pvt Ltd
- Thermo Fisher Scientific Inc
- InVitria
- Medxbio Pte Ltd
- Lazuline Biotech Private Limited
- Cyagen Biosciences
- Sartorius AG
- Akron Biotech
제14장 부록
LSH 26.01.22According to our new research study on "Recombinant Albumin Market Forecast to 2031 -Global Analysis - by Application and End User," the market is anticipated to grow from US$ 392.50 million in 2024 to US$ 767.54 million by 2031; the market is expected to register a CAGR of 10.1% from 2025 to 2031. The Recombinant Albumin Market growth is attributed to the increasing prevalence of liver diseases and associated conditions, advancements in biotechnological manufacturing and product development, and growing demand for albumin in critical care and emergency settings.
Recombinant albumin is a synthetic, non-animal-derived version of human serum albumin (HSA) produced through genetic engineering in host organisms such as yeast (Pichia pastoris, Saccharomyces cerevisiae), rice (Oryza sativa), or bacteria (E. coli). It is 100% identical in amino acid sequence to natural HSA but completely free of blood-borne pathogens, prions, and viral contaminants associated with plasma-derived albumin. Recombinant albumin is manufactured under cGMP conditions, offering superior batch-to-batch consistency, scalability, and regulatory safety. It is widely used as a stabilizer/excipient in biotherapeutics and vaccines, a critical component in serum-free cell culture media for biologics and cell/gene therapies, and an emerging therapeutic for hypoalbuminemia, liver disease, and regenerative medicine applications.
The Recombinant Albumin market in North America is segmented into the US, Canada, and Mexico. The recombinant albumin market in North America is experiencing significant growth driven by increasing clinical demand for safer and more consistent plasma protein products. According to the U.S. FDA, the prevalence of conditions requiring albumin therapy-such as liver cirrhosis, burns, and shock-has increased significantly. The CDC reported an estimated 40,000 new cases of liver cirrhosis annually in the US as of 2023. The growing adoption of recombinant albumin is also supported by advancements in biotechnology, leading to the development of safer, scalable, and ethically sustainable products. Notably, in 2022, the FDA approved new recombinant albumin formulations that reduce the risk of pathogen transmission compared to plasma-derived options, aligning with increasing safety concerns. Ongoing research and product innovations, such as the launch of recombinant albumin-based therapies for critical care and oncology, fuel market expansion. Government initiatives, including funding for biotechnology research and stricter regulations on plasma-derived products, encourage the shift toward recombinant alternatives. The COVID-19 pandemic underscored the importance of reliable biopharmaceuticals, further accelerating market growth. As of 2024, regulatory agencies continued to endorse recombinant albumin as a safer option for albumin therapies.
The US witnesses a demand for safer biologic inputs, rising prevalence of liver disease, and evolving regulatory expectations. A recent study found the prevalence of cirrhosis to be 2.6% of the US adult population. Individuals with liver cirrhosis often develop hypoalbuminemia and require albumin administration. The Food and Drug Administration (FDA) issued a draft guidance in April 2024 titled "Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products." In this draft, the agency highlighted concerns over the use of human- or animal-derived materials such as albumin and feeds in advanced therapies and encouraged manufacturers to justify alternatives. This regulatory momentum places recombinant human serum albumin (rHSA) and other non-plasma-derived albumin products in a favorable position as safer, defined alternatives.
Therapeutic Substitution of Plasma-Derived Albumin to Provide Market Opportunities in Future
A major opportunity for recombinant albumin lies in replacing plasma-derived human serum albumin (HSA) for therapeutic use, addressing safety and plasma-supply constraints. In China, human albumin demand exceeded 1,000 tons in 2024, with imports accounting for over 69% of total supply, according to the Wuhan Municipal Health Commission. To reduce reliance on plasma imports, the National Medical Products Administration (NMPA) approved the world's first rice-derived recombinant human albumin injection developed by Wuhan Healthgen Biotechnology in July 2025. In India, Shilpa Medicare Ltd. became the first domestic company to complete Phase I clinical trials for recombinant human albumin (20%) in August 2024, with Phase III trials authorized by CDSCO in November 2024. These regulatory milestones mark growing confidence in recombinant technology. With liver cirrhosis and hypoalbuminemia increasing globally, recombinant albumin presents a scalable, pathogen-free therapeutic substitute.
World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Chemical Society Publications, The U.S. Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services, Public Health Agency of Canada (PHAC), French National Institute of Health and Medical Research (INSERM), Italian National Institute of Health (ISS), The Korean Journal of Internal Medicine, the Saudi Press Agency (SPA), UAE Ministry of Health and Prevention (MOHAP) are among the primary and secondary sources referred to while preparing the Recombinant Albumin market report.
Table Of Contents
1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Analyst Market Outlook
- 2.2 Market Attractiveness
3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 3.3 Assumptions and Limitations
4. Recombinant Albumin Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Recombinant Albumin Market - Key Market Dynamics
- 5.1 Recombinant Albumin Market - Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints:
6. Recombinant Albumin Market - Global Market Analysis
- 6.1 Recombinant Albumin Market Revenue (US$ Thousand), 2021-2031
- 6.2 Recombinant Albumin Market Forecast Analysis
7. Recombinant Albumin Market Analysis - by Source
- 7.1 Human Recombinant Albumin
- 7.1.1 Overview
- 7.1.2 Human Recombinant Albumin: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 7.2 Bovine Recombinant Albumin
- 7.2.1 Overview
- 7.2.2 Bovine Recombinant Albumin: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 7.3 Other Sources
- 7.3.1 Overview
- 7.3.2 Other Sources: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
8. Recombinant Albumin Market Analysis - by Application
- 8.1 Excipient in Biotherapeutics and Vaccines
- 8.1.1 Overview
- 8.1.2 Excipient in Biotherapeutics and Vaccines: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 8.2 Cell Culture
- 8.2.1 Overview
- 8.2.2 Cell Culture: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 8.3 Drug Delivery
- 8.3.1 Overview
- 8.3.2 Drug Delivery: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 8.4 Diagnostics
- 8.4.1 Overview
- 8.4.2 Diagnostics: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 8.5 Other Applications
- 8.5.1 Overview
- 8.5.2 Other Applications: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
9. Recombinant Albumin Market Analysis - by End User
- 9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 9.2 Research Institutes
- 9.2.1 Overview
- 9.2.2 Research Institutes: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 9.3 Hospitals and Diagnostic Laboratories
- 9.3.1 Overview
- 9.3.2 Hospitals and Diagnostic Laboratories: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
- 9.4 Others End Users
- 9.4.1 Overview
- 9.4.2 Others End Users: Recombinant Albumin Market - Revenue and Forecast to 2031 (US$ Thousand)
10. Recombinant Albumin Market - Geographical Analysis
- 10.1 Overview
- 10.2 North America
- 10.2.1 North America Recombinant Albumin Market Overview
- 10.2.2 North America: Recombinant Albumin Market - Revenue, 2021-2031 (US$ Thousand)
- 10.2.3 North America: Recombinant Albumin Market Breakdown, by Source
- 10.2.3.1 North America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Source
- 10.2.4 North America: Recombinant Albumin Market Breakdown, by Application
- 10.2.4.1 North America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Application
- 10.2.5 North America: Recombinant Albumin Market Breakdown, by End User
- 10.2.5.1 North America: Recombinant Albumin Market - Revenue and Forecast Analysis - by End User
- 10.2.6 North America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.2.6.1 North America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.2.6.2 United States: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.2.6.2.1 United States: Recombinant Albumin Market Breakdown, by Source
- 10.2.6.2.2 United States: Recombinant Albumin Market Breakdown, by Application
- 10.2.6.2.3 United States: Recombinant Albumin Market Breakdown, by End User
- 10.2.6.3 Canada: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.2.6.3.1 Canada: Recombinant Albumin Market Breakdown, by Source
- 10.2.6.3.2 Canada: Recombinant Albumin Market Breakdown, by Application
- 10.2.6.3.3 Canada: Recombinant Albumin Market Breakdown, by End User
- 10.2.6.4 Mexico: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.2.6.4.1 Mexico: Recombinant Albumin Market Breakdown, by Source
- 10.2.6.4.2 Mexico: Recombinant Albumin Market Breakdown, by Application
- 10.2.6.4.3 Mexico: Recombinant Albumin Market Breakdown, by End User
- 10.3 Europe
- 10.3.1 Europe Recombinant Albumin Market Overview
- 10.3.2 Europe: Recombinant Albumin Market - Revenue, 2021-2031 (US$ Thousand)
- 10.3.3 Europe: Recombinant Albumin Market Breakdown, by Source
- 10.3.3.1 Europe: Recombinant Albumin Market - Revenue and Forecast Analysis - by Source
- 10.3.4 Europe: Recombinant Albumin Market Breakdown, by Application
- 10.3.4.1 Europe: Recombinant Albumin Market - Revenue and Forecast Analysis - by Application
- 10.3.5 Europe: Recombinant Albumin Market Breakdown, by End User
- 10.3.5.1 Europe: Recombinant Albumin Market - Revenue and Forecast Analysis - by End User
- 10.3.6 Europe: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.3.6.1 Europe: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.3.6.2 Germany: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.2.1 Germany: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.2.2 Germany: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.2.3 Germany: Recombinant Albumin Market Breakdown, by End User
- 10.3.6.3 United Kingdom: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.3.1 United Kingdom: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.3.2 United Kingdom: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.3.3 United Kingdom: Recombinant Albumin Market Breakdown, by End User
- 10.3.6.4 France: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.4.1 France: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.4.2 France: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.4.3 France: Recombinant Albumin Market Breakdown, by End User
- 10.3.6.5 Spain: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.5.1 Spain: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.5.2 Spain: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.5.3 Spain: Recombinant Albumin Market Breakdown, by End User
- 10.3.6.6 Italy: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.6.1 Italy: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.6.2 Italy: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.6.3 Italy: Recombinant Albumin Market Breakdown, by End User
- 10.3.6.7 Rest of Europe: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.3.6.7.1 Rest of Europe: Recombinant Albumin Market Breakdown, by Source
- 10.3.6.7.2 Rest of Europe: Recombinant Albumin Market Breakdown, by Application
- 10.3.6.7.3 Rest of Europe: Recombinant Albumin Market Breakdown, by End User
- 10.4 Asia Pacific
- 10.4.1 Asia Pacific Recombinant Albumin Market Overview
- 10.4.2 Asia Pacific: Recombinant Albumin Market - Revenue, 2021-2031 (US$ Thousand)
- 10.4.3 Asia Pacific: Recombinant Albumin Market Breakdown, by Source
- 10.4.3.1 Asia Pacific: Recombinant Albumin Market - Revenue and Forecast Analysis - by Source
- 10.4.4 Asia Pacific: Recombinant Albumin Market Breakdown, by Application
- 10.4.4.1 Asia Pacific: Recombinant Albumin Market - Revenue and Forecast Analysis - by Application
- 10.4.5 Asia Pacific: Recombinant Albumin Market Breakdown, by End User
- 10.4.5.1 Asia Pacific: Recombinant Albumin Market - Revenue and Forecast Analysis - by End User
- 10.4.6 Asia Pacific: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.4.6.1 Asia Pacific: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.4.6.2 China: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.2.1 China: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.2.2 China: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.2.3 China: Recombinant Albumin Market Breakdown, by End User
- 10.4.6.3 Japan: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.3.1 Japan: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.3.2 Japan: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.3.3 Japan: Recombinant Albumin Market Breakdown, by End User
- 10.4.6.4 India: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.4.1 India: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.4.2 India: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.4.3 India: Recombinant Albumin Market Breakdown, by End User
- 10.4.6.5 Australia: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.5.1 Australia: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.5.2 Australia: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.5.3 Australia: Recombinant Albumin Market Breakdown, by End User
- 10.4.6.6 South Korea: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.6.1 South Korea: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.6.2 South Korea: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.6.3 South Korea: Recombinant Albumin Market Breakdown, by End User
- 10.4.6.7 Rest of APAC: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.4.6.7.1 Rest of APAC: Recombinant Albumin Market Breakdown, by Source
- 10.4.6.7.2 Rest of APAC: Recombinant Albumin Market Breakdown, by Application
- 10.4.6.7.3 Rest of APAC: Recombinant Albumin Market Breakdown, by End User
- 10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Recombinant Albumin Market Overview
- 10.5.2 Middle East and Africa: Recombinant Albumin Market - Revenue, 2021-2031 (US$ Thousand)
- 10.5.3 Middle East and Africa: Recombinant Albumin Market Breakdown, by Source
- 10.5.3.1 Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast Analysis - by Source
- 10.5.4 Middle East and Africa: Recombinant Albumin Market Breakdown, by Application
- 10.5.4.1 Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast Analysis - by Application
- 10.5.5 Middle East and Africa: Recombinant Albumin Market Breakdown, by End User
- 10.5.5.1 Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast Analysis - by End User
- 10.5.6 Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.5.6.1 Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.5.6.2 Saudi Arabia: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.5.6.2.1 Saudi Arabia: Recombinant Albumin Market Breakdown, by Source
- 10.5.6.2.2 Saudi Arabia: Recombinant Albumin Market Breakdown, by Application
- 10.5.6.2.3 Saudi Arabia: Recombinant Albumin Market Breakdown, by End User
- 10.5.6.3 South Africa: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.5.6.3.1 South Africa: Recombinant Albumin Market Breakdown, by Source
- 10.5.6.3.2 South Africa: Recombinant Albumin Market Breakdown, by Application
- 10.5.6.3.3 South Africa: Recombinant Albumin Market Breakdown, by End User
- 10.5.6.4 United Arab Emirates: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.5.6.4.1 United Arab Emirates: Recombinant Albumin Market Breakdown, by Source
- 10.5.6.4.2 United Arab Emirates: Recombinant Albumin Market Breakdown, by Application
- 10.5.6.4.3 United Arab Emirates: Recombinant Albumin Market Breakdown, by End User
- 10.5.6.5 Rest of Middle East and Africa: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.5.6.5.1 Rest of Middle East and Africa: Recombinant Albumin Market Breakdown, by Source
- 10.5.6.5.2 Rest of Middle East and Africa: Recombinant Albumin Market Breakdown, by Application
- 10.5.6.5.3 Rest of Middle East and Africa: Recombinant Albumin Market Breakdown, by End User
- 10.6 South and Central America
- 10.6.1 South and Central America Recombinant Albumin Market Overview
- 10.6.2 South and Central America: Recombinant Albumin Market - Revenue, 2021-2031 (US$ Thousand)
- 10.6.3 South and Central America: Recombinant Albumin Market Breakdown, by Source
- 10.6.3.1 South and Central America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Source
- 10.6.4 South and Central America: Recombinant Albumin Market Breakdown, by Application
- 10.6.4.1 South and Central America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Application
- 10.6.5 South and Central America: Recombinant Albumin Market Breakdown, by End User
- 10.6.5.1 South and Central America: Recombinant Albumin Market - Revenue and Forecast Analysis - by End User
- 10.6.6 South and Central America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.6.6.1 South and Central America: Recombinant Albumin Market - Revenue and Forecast Analysis - by Country
- 10.6.6.2 Brazil: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.6.6.2.1 Brazil: Recombinant Albumin Market Breakdown, by Source
- 10.6.6.2.2 Brazil: Recombinant Albumin Market Breakdown, by Application
- 10.6.6.2.3 Brazil: Recombinant Albumin Market Breakdown, by End User
- 10.6.6.3 Argentina: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.6.6.3.1 Argentina: Recombinant Albumin Market Breakdown, by Source
- 10.6.6.3.2 Argentina: Recombinant Albumin Market Breakdown, by Application
- 10.6.6.3.3 Argentina: Recombinant Albumin Market Breakdown, by End User
- 10.6.6.4 Rest of South and Central America: Recombinant Albumin Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
- 10.6.6.4.1 Rest of South and Central America: Recombinant Albumin Market Breakdown, by Source
- 10.6.6.4.2 Rest of South and Central America: Recombinant Albumin Market Breakdown, by Application
- 10.6.6.4.3 Rest of South and Central America: Recombinant Albumin Market Breakdown, by End User
11. Competitive Landscape
- 11.1 Heat Map Analysis by Key Players
- 11.2 Company Market Share Analysis, 2024
12. Industry Landscape
- 12.1 Overview
- 12.2 Market Initiative
- 12.3 Merger and Acquisition
- 12.4 Other Developments
13. Company Profiles
- 13.1 CSL Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Merck KGaA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 HiMedia Laboratories Pvt Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Thermo Fisher Scientific Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 InVitria
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Medxbio Pte Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Lazuline Biotech Private Limited
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Cyagen Biosciences
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 Sartorius AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Akron Biotech
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
- 14.1 About The Insight Partners
- 14.2 List of Abbreviations
